Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New System for Treating Cartilage Lesions

By HospiMedica staff writers
Posted on 29 Aug 2006
A cartilage surface implant system is designed for the treatment of patello-femoral disease, localized cartilage lesions, and defects in the major joints.

The HemiCAP (contoured articular prosthetic) resurfacing system replaces damaged cartilage surfaces with contoured implants that are matched to the patients' anatomy using a patented, intra-operative, three dimensional (3D) mapping technology. More...
The system is comprised of three elements: the 3D mapping technology, a set of instruments to map and prepare the damaged area, and an off-the-shelf rounded, cap-like implant made from a cobalt chrome alloy with a central post on the implanted (bone) side. The system can be used for various knee, shoulder, hip, and great toe applications.

The surgical procedure begins the same way as all arthroscopic procedures. Through a small access incision an arthroscope is inserted into a cannula, which is used to protect it and also allow for saline fluid to flow into the joint. Through another incision, different instruments are inserted for use during the operation. When an articular defect is confirmed, the central axis in the middle of the defect is located and a component that looks like a screw is implanted to establish the mechanism for anchoring the resurfacing implant. Using this first component as a central axis, several specially designed instruments are introduced to map the contours of the patient's articular cartilage surrounding the defect and to prepare the tissue in and around the defect itself for the resurfacing implant. Once the site is prepared, the HemiCAP resurfacing implant is brought into position and seated.

The HemiCAP system is intended to provide an effective interim means for managing pain and disability in middle-aged patients until a total joint-replacement treatment option becomes more necessary, and is part of a clinical treatment strategy to help avoid early-age-revision scenarios. The prosthetic may also provide a treatment option for the older patient who may not tolerate the morbidity of a total joint-replacement procedure. The implants and instruments are designed to remove a minimal amount of bone stock, preserve functional structures and tissues, and allow for an uncomplicated removal in the event of revision.

"The principal advantage of the Arthrosurface system is that it is an intuitive technology that allows for very accurate matching of the implants to the affected cartilage surface, without altering the biomechanics of the joint,” said Dr. Anthony Schepsis of the Boston University Medical Center (MA, USA).

The HemiCAP system was developed by Arthrosurface (Franklin, MA, USA) and is available in the United States, Europe, Australasia, Latin America, and South Africa.



Related Links:
Arthrosurface

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.